Connect with us


Tetra Bio Pharma Inc (OTCMKTS:TBPMF)’s Subsidiary Submits OTC DIN Applications To Treat Hemorrhoids, Joint And Muscle Pains, And Offer Relief To Aches



Tetra Bio Pharma Inc (OTCMKTS:TBPMF)’s wholly-owned subsidiary – Tetra Natural Health, has submitted applications to Health Canada. The first OTC DIN application submitted on November 15, 2019, is to offer treatment for hemorrhoids. Its second application submitted on November 26, 2019, is to provide relief to patients suffering from joint and muscle pains related to sprains, bruises, strains, lumbago, backache, rheumatic pain, arthritis pain, and pain in ligaments and tendons. It also offers temporary relief to aches.

Self-care therapies

The OTC (over the counter) product line developed by Tetra comprises beta-caryophyllene. It is developed to offer self-care therapies to the patients and pharmacists by working directly on the CB2 receptors. The company plans to introduce these OTC pain relief products to get a pie of the OTC market, which is estimated at $19 billion. CRO and Chief Executive Officer of Tetra Bio-pharma, Dr. Guy Chamberland, said the company is focused on bringing proven therapies to the patients.

Expects a commercial launch in 2020

Tetra plans to launch OTC pain relief medicines commercially in early 2020 in the pharma retail outlets of Canada. The company is in negotiations with several firms to distribute and sell the products. It also plans to launch these products in the US next year. Tetra is applying for an NDC (National Drug Code) with the US FDA and negotiating with prospective bidders for contract manufacturing in the US.

Resumes clinical trial in cancer patients

With the nod of the US FDA, Tetra resumed clinical trial of (the previously halted) Plenitude in patients who have cancer in advanced stages. The company conducts the clinical trial for QIXLEEF to treat uncontrolled pain in cancer patients. FDA gave the nod after reviewing the quality profile of Tetra that includes mycotoxin quality information and on confirming that adequate safety measures are in place to safeguard the patients. Tetra would quickly enroll patients for its clinical trial.

Chamberland said the company is pleased to get FDA nod to proceed with the clinical trial of Plenitude. He said the company would launch the clinical trial in the coming days on seventy-eight adult patients. During the four-week trial, Tetra would evaluate the efficacy and safety of the inhaled PPP001 in cancer patients suffering from uncontrolled pain.


Terrascend Corp (OTCMKTS:TRSSF) Speaks Out About Its Two Year Term Loan



Terrascend Corp (OTCMKTS:TRSSF) has today announced the extension of its credit facility. It has also disclosed that JW Asset Management LLC will be entrusted with the management of funds. The maturity date for the mentioned faculty, which is said to be worth US$75 million, will be on December 18, 2019.

Ackerman’s take

The Executive Chairman of TerrAscend Jason Ackerman says that they have been hoping to witness the improvement of the banking, regulatory, and capital markets. He says that this is the best time for the company to obtain a non-dilutive source of business financing.

The Chief Investment Officer of JW Asset Management Jason Wild has been very supportive, according to this leader. He adds that they are putting in efforts targeted at expanding their hemp CBD market opportunities in New Jersey, Canada, Pennsylvania, and California.

Analysts have also aired out their views saying that TerrAscend has got all that it needs to uphold organic growth and profitability.

Wild’s remarks

Jason Wild has also spoken about the matter. The official says that he was impressed by JW Asset Management’s move last year to provide the original credit facility. He remembers quite well that this was the same time that TerrAscend had just kick-started its U.S. growth strategy after attaining third-quarter revenues amount to $1.8mm. The company upheld remarkable performance considering that it fetched $100mm in its previous quarter.

Wild says that he is amazed by the pace of the acquisitions and the organic growth as well. The other thing he has spoken about is the super license buildout in NJ.

He has also promised that the JW Asset Management won’t stop in its efforts to support Jason Ackerman, together with his team, achieve immense business success. He asserts that it is of the essence, adding value both as a shareholder and a lender as well.

The signing of this loan deal is set to take place at a later date. That is when Terrascend Corp will move ahead to unveil the definitive terms associated with the deal.

The company has also disclosed that it is looking into ways to enhance its products and services further.

Continue Reading


Lift & Co Corp (OTCMKTS:LFCOF) To Expand Business Operations In The US



Lift & Co Corp (OTCMKTS:LFCOF) is quite pleased about the addition of the adobe advertising capabilities to its business undertakings. The Adobe Advertising Cloud demand-side-platform (DSP) is quickly getting adopted across the expansive and fast-growing digital marketing landscape. This cloud solution is growing quite popular among the various media and digital platforms for its effectiveness in reaching out to customers.

Details about the business strategy

It is also worth noting that this solution is powered by Nielsen. Its power lies in its capabilities in terms of helping the cohesion clients strike a much better understanding of their target consumer segments. One of the aspects that clients would like to know is the purchase habits of the consumers. This helps in making proper plans as well as in proper delivery to these particular segments.

The CEO of Lift & Co Matei Olaru has been closely watching cannabis companies that have been successful in establishing legacy brands. He has seen how they have been going about the whole act of introducing new products into the market. One thing that is quite clear to him is that they have been failing massively when it gets to the leveraging of outstanding CPG-like approaches.

The state of affairs

According to the official, actionable consumer insights are important for business growth and expansion. He has termed the Cohesion Segmentation an outstanding strategy for the modern business. He adds that any progressive businesses in the cannabis segment need to take it up to reach consumers effectively.

The targeted digital advertising capabilities are taking over the business world by storm, according to analysts. It was back in 2019 that the company announced the unveiling of its Cohesion platform. After just a short while, major changes are being witnessed already. Quite a significant number of licensed producers are resorting to it on a countrywide scale to enjoy the associated benefits.

Lift & Co has also announced its plan to expand more into the United States. It has termed the business collaboration with Enlighten a major step forward towards attaining success. The partnership is going to help Lift succeed in its efforts in the development of leading cannabis products.

Continue Reading


Zelira Therapeutics (OTCMKTS:ZLDAF) Intends To Expand HOPE® Distribution In The US



Zelira Therapeutics (OTCMKTS:ZLDAF) has disclosed details about its plant to move its HOPE® Franchise to Louisiana. The company hopes to generate instant revenues through licensing arrangements. It will be asking for an up-front fee, after which it will expect to be paid some ongoing royalties.

A close outlook

The business guru has said that it is not going to speak out about the commercial terms of the deal. It intends to keep the terms of the deal confidential.

It was in May 2019 that the company unveiled its Franchise in Pennsylvania, and this deal was with Ilera Healthcare. This agency is known to hold a state license.

HOPE® has been showcasing outstanding performance since its introduction to the market. It has been fetching high revenues all along. This makes it stand out in a great way as the best selling formulated medicinal cannabis product in the state of Pennsylvania.

The current state of affairs

Zelira Therapeutics Ltd is a product of the merger between Ilera Therapeutics LLC and Zelda Therapeutics Limited. Zelda Therapeutics is a biopharmaceutical company based in Australia, whereas Ilera Therapeutics is a cannabinoid and medicinal cannabis company in Pennsylvania.

Reports indicate that these two companies will benefit from having direct access to the US, which is undoubtedly the biggest medicinal cannabis market globally.

The other thing about the US is the fact that it has over four million registered patients, and this spells out the presence of a huge market for products. This is not the only market these companies have access to. There are other markets in the United Kingdom, Germany, and Australia.

Analysts have applauded this merger, outlining that it is all about fostering a long-term supply and distribution relationship. A lot of people are now resorting to cannabis products for their general wellness needs, and there is a need to ensure they access enough of the pharmaceutical-grade medicinal cannabis. Companies are competing to develop wide-ranging products to supply large populations, and this is resulting in the development of top quality products.

Zelira says it has plans underway to unveil its global strategy in Louisiana. If all moves according to plan, it will have accomplished this by its first-quarter of 2020.

Continue Reading


Whats Hot